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ABSTRACT
Generics in the pharmaceutical industry have been instrumental in reducing overall healthcare cost and
allowing for greater dispersal of life saving drugs to the general population. The Hatch-Waxman Act of
1984 played a critical role in changing the landscape of the pharmaceutical industry and providing
legislation for an abbreviated regulatory pathway for generic drugs. The conversation has shifted to the
need to implement similar regulatory paths for generics of biologics. First generation biologic patents
have or are geared to expire within the next five years, providing a great opportunity for generic
companies in this space to enter. Biologic generics, termed biosimilars or follow-on biologics, are more
difficult to evaluate due to the complex nature of the molecule and the variables involved in the
development and manufacturing process. This research seeks to understand the current debate in the
biosimilar conversation, and examine whether there is a clear regulatory path to market for biosimilars
using epoetin as a case example across the three main markets; US, Europe and Japan.
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Chapter 1: Introduction
Generic forms of biologic products are now developed and discussed as key products to reduce
overall cost and help maintain profitability for healthcare companies. These generic products are
termed 'biosimilars' or 'follow-on biologics." Many pharmaceutical and biotechnology companies
face the strategic decision whether to enter the biosimilars marketplace. A number of key factors,
including the "patent cliff' paradox for current branded biologics and the shift in medical practice to
utilize targeted high-value biologic therapies, make the biosimilar market a very attractive possibility.
The current questions for companies concerned with pursuing biosimilars are:
" Is there a "path" to market for biosimilars?
* How do these paths differ across the three most developed regulatory markets; US,
Europe and Japan?
One fundamental question is whether or not pharma and/or biotech companies should pursue
biosimilar therapies based on the regulatory 'cost' associated with entry. Beyond just the monetary
cost of drug evaluation, there is also the risk of uncertainty with biosimilars. This thesis examines
whether there is a clear regulatory path to market for biosimilars using epoetin as a case example
across the three main markets; US, Europe and Japan. An in-depth analysis of the regulatory
documents will be conducted and presented in a case study framework.
The structure of the thesis is as follows:
* Chapter 2: A historical look at the pharmaceutical regulatory pathway development for
generics and an in-depth analysis of the key regulatory milestones that molded the direction
of the generic conversation. Then, a robust outline will be provided as to how small
molecules generics are compared to their branded equivalent through a product driven
method.
* Chapter 3: A historic look at the biologics industry and regulatory pathway for both
branded products and biosimilars.
* Chapter 4: Identifies the key areas (scientific, clinical, and political) that are hotly contested
in the biosimilar debate. This chapter will take a look at the strong opinions held by the
research-based companies (Large Pharma/Branded Biologics companies) and how those
differ from those of generic companies that wish to enter the biosimilar space.
Chapter 5: One of the missing links in the biosimilar conversation is a comprehensive
checklist for biosimilar companies interested in entering the main world biologics markets.
In theory, a global biosimilars approval pathway would greatly reduce cost for biosimilar
manufacturers, thereby encouraging more players in the market and spurring competition to
reduce biosimilar price. However, with the complexities and uncertainties of determining
biosimilar equivalence, there is a slim chance that a global regulatory pathway would ever
develop due to lack of consensus. Therefore, biosimilar manufacturers will need to gain
approval through the complex regulatory processes for each market they wish to enter. With
biosimilar guidelines in its infantry, there has been a lack of transparency as to what steps are
needed to be takein within each country to gain approval (Figure 1). This chapter will
provide potential biosimilar companies a checklist of key submission criteria for each of the
three regulatory pathways (EU, US and Japan). Human Erythropoietin, or epoetin as it is
referred to as a biologic product, will be the case example used to discuss the regulatory
pathway throughout the thesis. A background will be provided about epoetin here.
Requirements for bioimilair &ug approval
* Physlochemical and biological compwison with reference product
0
* * Comparative preclirilci toothing with referen~ce product
S * 1* Compaative pharmacokineticlpharmucodynamlc Phase I studies with reference product
0
Comparative Phase Ill studies with reference product from either the EU or US
Source: Datarronitar; Schwarzenberger, 2009 DATAMONITOI
Figure 1: Requirements for Biosimilar Drug Approval in the US, EU and Japan: The connecting line for the fourth component, comparative
phase 111 studies, is implying that phase 111 study results from these three countries could be interchangeable for regulatory approval if a global
biosimilars pathway is created.
.......... ........... ..... .......... -,".- I'll
* Chapter 6: A discussion of what learning's have been gained in the biosimilar regulatory
space and what actions must be taken that are known with certainty to provide information
about how 'similar' a biosimilar is to its reference product. A revisit of the biosimilar debate
and a discussion of key areas of biosimilars that are creating value in the market will be
presented. In conclusion, a final regulatory guideline will be provided.
* Appendices: A robust analysis of the biosimilar market for both the short and long-term.
Chapter 2: History of Pharmaceutical Regulatory Pathway
Introduction of Generics
Generic is a common term in the prescription drug business, and is defined as a drug that is
produced and sold without patent protection under its chemical name. The generics market (Gx
Market) is largely included as a branch of the pharmaceutical industry known as the small molecules
industry. Although sales have generally soared in recent years, generics are predominantly adopted
in countries with high healthcare expenditure. In the US for example, healthcare expenditures
exceeded $2.2tn in 2007, accounting for 16% of GDP. Prescription medication was over $200bn of
that expenditure (5). With the cost-cutting pressure within the healthcare system over the past few
decades, generics have risen as a key player in aiding to reduce the cost burden.
Generics are able to extract a greater value from the drug than what is current being offered by the
branded version usage levels. They provide access to the average individual to medications through
lower costs that are driven by high competition and high volume uptake. Patients are given further
incentives to use generics through payer provisions such as waiving generic co-payment as seen in
the US Medicare system. However, the mission of generics is very similar to that of its innovator. It
maintains its first priority to ensuring patient safety, and does this through understanding the drug's
characteristics and its impact on patient safety. Generic companies also maintain a principle of
respecting the innovator's intellectual properties (29,30,31,30).
The 100 Year Evolution of Pharmaceutical Drugs
The small molecule/pharmaceutical drug industry is relatively speaking more mature, with medieval
literature referencing alchemist as developers and distributors of chemically synthesized drugs.
These drugs were defined and regulated in the U.S. in 1906 with the enactment of the Food and
Drugs Act of June 30, 1906 (24,26). The defining of a drug and more specifically, a 'new drug', is
critical in understanding the evolution of the generics industry and the criteria in which generic vs.
branded drugs are compared to one another.
A 'drug' is identified as the grouping of products that are subject to regulation, and are 'articles
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases in man and
articles (other than food) intended to affect the structure or any function of the body of man..."
More clarity was given to this definition through the 'grandfather clauses' of 1938, in which the New
Drug Application (NDA) was introduced (24,26).
Based on this regulatory knowledge at the time, end product testing of chemically synthesized drugs
was used to determine product performance and safety. Since these drugs were either produced
through chemical reactions, or isolated and purified from plants, the purity of these drugs can be
easily determined. Since 1938, the new drug application (NDA) has been the vehicle in which
pharmaceutical drug makers have used to gain approval and marketing/sales authorization in the
US. Table 1 provides a checklist for parties interested in bringing a product through this approval
process.
1'nysical unaractenstics: molecular weignt, primary & X
secondary structures, etc.
Chemical Characteristics: molecular formula, chemical
strucutre
Specifications of drug substance (active ingredient) X
stability X
purity X
pharmacokinetic/pharmacology/toxicology X
studies for absorportion, distribution, metabolism and
Bioavailability/bioequivalence
biologics will have such data)
x
x
x
x
Description and analysis of each clinical pharmacology
study of the medicinal product( comparison of human X
data with animal data)
Pharmacokinetic & Toxicology Studies X
Description and analysis of each controlled clinical X
study
Clinical Effectiveness for the clinical indications.
Evidence for dosage and administration required.
Clinical Safety: studies of assessment of absorption,
distribution, metabolism, and/or elimination of drug
Summary of benefits and risks of the medicinal
Droduct in its intended use x
x
x
x
Tablel: Regulatory Checklist for New Drug Application (NDA)(26): A breakdown of the key regulatory categories; product characteristics,
GMP, Clinical and other.
......................
Historically, there has been ambiguity with the FDA's definition of 'new drug'. This has been
critical in the confusion of what a generic drug is and how it is later evaluated. The definition of a
'new drug' can be interpreted in three ways:
1. Every drug that is introduced is a 'new drug'. (Therefore generics would be required to pass
stringent general recognition among experts to escape new drug classification.)
2. Drugs are classified as 'new' if the active ingredient is different. (Therefore any generic copy
of the drug that contains the same active ingredient can escape the new drug classification,
and pre-market approval requirement)
3. A group of drug products that have the same active ingredient, same dosage form, and the
same indication (26).
The major controversy with this legislation was whether the term new drug was intended to refer to
all manufacturer's version of the same active ingredient marketed in the same dosage form and sold
for the same indication or any variation of these three criteria (i.e. same dosage and same indication
but not same active ingredient).
Continued revisions by the FDA have tried to address the issues around what is a new drug. Key
legislation passed in 1984 paved the way for the generic entrance into the pharmaceutical industry.
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as
the Hatch-Waxman Act, explicitly permitted drug approval based on an abbreviated new drug
application (ANDA) and allowed for generic copies of FDA approved pioneered products to apply
without full safety and efficacy testing. The Hatch-Waxman Act provided guidelines for generics to
enter the market through an approval process that required bioequivalence studies as opposed to
clinical data, and granted additional market exclusivity (not to exceed five years) in lieu of not having
patent protection in the development process. Figure 2 provides a sampling of the requirements of
the 505 regulatory pathway family, which is the regulatory path established for generic entrance (26).
Required information:
-Official & proprietary name
-date of approval
-Patent information
-In vitro/in vivo bioequivalence studies
-NDAs for generic copies DO NOT require full
safety and efficacy testing
- Can submit published reports of those
studies or otherwise achieved approval
without actual submission of the safety
and effectiveness data
Figure 2: Abbreviated New Drug Application Pathways for Pharmaceutical Candidates (26): The 505 pathways were created through the
Hatch-Waxman Act, which allowed for abbreviated new drug applications for generic drugs.
The Hatch-Waxman Act, specifically the 505(b) provision that allowed generics to submit literature
and external clinical data as evidence of the safety and efficacy of their drug, was strongly opposed
by the pharmaceutical industry. Pharmaceutical companies argued that external data was not
sufficient to prove safety and efficacy of generics and that full-scale clinical trials should be required
for regulatory approval. However, the FDA rejected the challenge and continues to allow clinical
trial data to be submitted as part of the application process that was not collected directly by the
generics company (26).
The positive effect of the Hatch-Waxman Act was astounding. Prior to the introduction of this act,
the market saw very little penetration of generic products, which meant fewer drivers to decrease the
overall healthcare cost burden. Less than 40% of all top-selling drugs post patent expiration had a
generic option available prior to 1984, and less than 20% of all prescriptions were generic. The
benefit to society, both in terms of lowering healthcare costs and providing accessibility of life
saving therapies to a greater population was enormous. The introduction of these guidelines have
allowed for generic drugs to be more easily distributed and prescribed to patients. In 2007, generics
accounted for 65% of total prescriptions, with a steady growth rate of 8-10% per year(5). It is
evident that generic drugs in the small molecule industry have been a proven success and has
positively impacted the US (25).
In 2001, a global initiative took place to allow for submission of data in the same format and content
across the three major markets (Europe, US, Japan) for regulatory approval. In the past, submission
requirements vary depending on the function of a drug. However, regulatory bodies across these
three markets came to a consensus on how to create a structured framework for drug manufacturers
to follow in order for them to collect the necessary data and product research to gain approval
(25,26).
Therefore, a new drug pathway and an abbreviated pathway have been created for regulatory
approval of small pharmaceutical molecules. Table 2 provides a checklist and comparison of the
regulatory pathway between new drugs and generics. Generics have greatly benefited from the
abbreviated pathway, as they are not required to invest in high cost studies (clinical trials, non-
clinical trials) that therefore decrease the high barrier to entry and allow for cost savings to be
enjoyed by the entire healthcare system. The commercialization of generics requires 3-5 years to
develop at a cost of $1-5million, 200-fold less than the cost to innovate and develop a new small
molecule drug (31).
ra1ybolm nIaI4%WuZues. ILIIVnnUIU WrIuL, FUJUUy 0X x x
secondary structures, etc.
Chemical Characteristics: molecular formula, chemical
strucutre
Specifications of drug substance (active ingredient) X X
stability X X
purity X X
pharmacokinetic/pharmacology/toxicology X X
studies for absorportion, distribution, metabolism and I
x
x
Bioavailability/bioequivalence studies (very few X
biologics will have such data)
Description and analysis of each clinical pharmacology
study of the medicinal product( comparison of human X
data with animal data)
Pharmacokinetic & Toxicology Studies X
Description and analysis of each controlled clinical
study
Clinical Effectiveness for the clinical indications.
Evidence for dosage and administration required.
Clinical Safety: studies of assessment of absorption,
distribution, metabolism, and/or elimination of drug
Summary of benefits and risks of the medicinal t
product in its intended use
Safety update RportsU (four months post NDA' X
submission)II
Table 2: Branded and Generic Regulatory Approval Pathway Checklist that is a product driven process
Chapter 3: The Evolution of Biologics and the Regulatory Pathway
The Birth of the Biologics Industry
Biologic therapies have in essence been in existence since the turn of the 2 0 th century to combat
infectious disease epidemics such as polio, typhoid, and cholera. They differ from small molecules
in that they are "complex mixtures that are not easily identified or characterized" and are derived
from living sources, such as humans, animals, plants and microorganisms (24). In the past century,
the definition of biologics has expanded to include viruses, therapeutic serum, toxin, antitoxin,
vaccine, blood, and blood components or derivative allergenic products or analogous product
applicable to the prevention, treatment, or cure of a disease or condition of human beings. Biologics
can be found in two forms: as a drug or medical device.
The discovery of vaccines was the first biologic to come to market. At this time in history, there
was a lack of understanding of immunology and microbiology. Therefore, there was very little
understanding of the variables involved in the manufacturing of these biologic products and the
effects of those variables on safety and efficacy. The crude manufacturing methods predominately
used animal models to produce the vaccines, and these methods were poorly understood. Only after
the 1901 antitoxin episode, where 10 children were given diphtheria antitoxin contaminated with
tetanus contracted from horses used in production, did the FDA step in to regulate biologics(24).
Due to the early tragedies such as the diphtheria antitoxin incident, regulators quickly learned that
end product testing was not sufficient to determine product performance and safety. Many
biologics work through immune response systems, and therefore a very small amount of active
substance is required to trigger these responses. Hence, the extent to which a biologic had to be free
of all impurities was in question and dependent of clinical safety profiles. Another issue was that
until the most recent past, analytical methodologies and protein chemistry were not sensitive enough
to characterize these complex products. Because of these intricacies in safety testing, a new
regulatory approach was developed specifically for biologics. Regulatory bodies focused on
controlling the product's manufacturing facility and method of manufacturing, since the variables in
these processes highly influence safety and effectiveness of the biologic (24).
The process of regulating biologics began with The Biologics Control Act of 1902, which was
passed to regulate the manufacturing process of biologics. This act began a series of future
legislation that focused on the manufacturing process of biologics to determine safety and efficacy,
rather than mirror the product-driven regulation of the pharmaceutical industry (Refer to Figure
3)(24).
1948: Division of Biologics
Cortol was made part of the
Nalioral Micobiological
1937: Estabishmaentof
DIvision of Biologics
Contol
1972. F:A
taees
rusponsibirity of
regulating
biologics
2010: Biasimilar
Regulatory Pathway
created thmugh
Healthcare Reform Act
199: creation of
Biological Lcense
Appicaton BLA)
- ________________________ - - ~1 .1
1970: amendment Ito hvincud blood,
blood camlponai and allerganic
extracts to biologics de&Mnn
1955: Creation of the
Division of Biological
Standards
Figure 3: Timeline of Biologic Regulation in the US(24,26) : All the previous legislation and events leading to the Biosimilar Regulatory
Pathway created through the Healthcare Reform Act of 2010.
..... . . ...... .....
1902: Bioloies
Control Act
The further understanding of immunology coupled with the genomics era in the 1970s and 1980s
led to the explosion in scientific advancement and the creation of the biotechnology industry. The
complexity of these new products led to significant debate and restructuring in regulator's thought
process in monitoring these products. Different regulatory approval processes were put in place to
deal with the fundamental differences between chemically derived drugs and biologics.
Biotechnology and the biologics industry is a fairly young industry with a limited number of past
experiences to build on. It was introduced into mainstream medicine in the early 1980s, with the
arrival of recombinant insulin, human growth hormone, and erythropoietin. The key to biologic
regulation is to be able to prove that it the therapy is 'safe, pure and potent'. Biologics require the
same evidence of safety and effectiveness, publication of clinical trial data, post-approval testing and
risk evaluation and mitigation strategies as is required for pharmaceutical drug approval (Table 3).
However, biologics are unique because its' manufacturing process is the key vehicle required for
characterization rather than its' precise composition. Therefore, by definition, two biologic agents
from different production systems can never be identical (12).
secondary structures, etc.
Chemical Characteristics: molecular formula, chemical
strucutre
Specifications of drug substance (active ingredient) X
stability X
purity X
consistency of manufacturer of the drug substance X
Description of analytical testing performed on the
manufacturer's referece standard lot and qualitying lots X
to characterize the drug substance.
pharmacokinetic/pharmacology/toxicology X
studies for absorportion, distribution, metabolism and
Isioavaiiablty/Dioequivalence
biologics will have such data)
X
X
X
X
X
X
X
X
x
Description and analysis of each clinical pharmacology
study of the medicinal product( comparison of human X
data with animal data)
Pharmacokinetic & Toxicology Studies X
Description and analysis of each controlled clinical
study
Clinical Effectiveness for the clinical indications.
Evidence for dosage and administration required.
Clinical Safety: studies of assessment of absorption,
distribution, metabolism, and/or elimination of drug
Summary of benefits and risks of the medicinal X
X
Xx
Table3: Regulatory Checklist for New Drug Application for Biologics: The biologic regulatory pathway expands on the small molecule
pathway by including good manufacturing practices. Due to the difficulties in analyzing the end product of biologics, bioequivalence and
bioavailability tests are not always submitted because they can not be obtained.
... .. .. ........
Biologics have accounted for 10% of the new molecule entities (NMEs) from the period of 1950-
2008 in the US(27). (During this period, -1200 NMEs were approved in the US). It is important to
note that biologics did not enter the market until 1982 (Figure 4).
a 60-
Small molecules (NMEs)
50 - Biopharmaceuticats (NBEs)
dL -Total
zo
z 40-
Z 30-
220-
E
z10-
Figure 4: History of New Drug Approval (27): Timeline of approvals of new molecular entities (NMes) and new biological entities (NBEs) by
the US Food and Drug Administration (FDA) between 1959 and 2008.
Biologics are the wave of the future for medical therapies. The pharmaceutical industry is
transitioning away from its strategy of small molecule products towards more specialized, secondary
care indications with the use of biologic therapies. Biologic sales currently account for $75bn
worldwide, with annual growth projections of 15%. Biologics are perceived to be a lucrative
industry due to its ability to target unmet needs for life threatening and rare diseases such as cancer,
HIV, and rheumatoid arthritis to name a few. With the average biologic costing more than 22x per
dose in comparison to pharmaceutical drugs, it has become a lucrative proposition for both
entrenched pharmaceutical players and new entrants. In summary, biologic therapies will drive
future sales growth because they focus on unmet disease areas, demand a high price point, and
incumbents maintain a high barrier of entry due to the difficulty in manufacturing formulation
(29,30,31,32). Figure 5 shows the projected growth in biologics therapies.
...... .........
...... . ..........
Cardiovascular, Endocrine, CNS, Heniatological , Oncolo gy, Immun olo gy and
slusculoskeletal, Respiratory, Other Inflammation, Infectious
Gastrointestinal Disease, Urological
Biologics
Vaccies
Small
molecules
Bubble size illusirates forecast 2009-2014 sales growlh as a percentage of 2009 annual sales.
Dotted line denotes negative sales growth.
Source: DElamintr, Big Phwms Perfomane Before, Dunig amd Beyund Me Gkbal
Recessii, DMHC2582, Noventer 209 DATAOMNITOR
Figure 5: Forecasted Sales Growth for Pharmaceutical/Biologic Drugs from 2009-2014 (29,30,31,32)
Drivers of Biologic Growth
In 2009, 27% of all new drug applications represented biologics (29). Incentives to continue this
growth in biologic entrants include the following:
Large Pharmaceutical Focus: Large pharma is facing a loss of sales in the immediate future due to
patent expiration of key blockbuster drugs and the healthcare trend away from primary care, small
molecule therapy. Biologics market is an expanding market, with a shift in medical practice towards
secondary care through use of these high-value biologic therapies. Key therapeutic growth drivers
for 2010-2014 include monoclonal antibodies, injectable drugs, and oncology related therapies (29).
Therefore, the pharmaceutical industry is seriously exploring the biologics space as an area where
they hope to make investments to offset their future profit losses.
.................................... ..... 
Regulatory Incentives: Regulatory bodies such as the FDA and EMEA are encouraging companies
to focus on unmet disease areas, also defined as 'orphan drugs', through tax credits, regulatory
assistance and the potential to gain access to an accelerated approval system (29,32).
Customer Perception: The hot social topic in medicine is the concept of 'personalized medicine', in
which medicines are tailored to individual patients based on their own unique profile. Biologic
therapies cater to this increasing social need to take modern genetic and science knowledge to create
medications that are applicable to a unique individual and/or population (21).
The Introduction of Biosimilars
Biosimilars, commonly referred to as biogenerics and follow-on biologics, are a biological product
that is highly similar to a reference product in terms of safety, purity and potency (24,25). In
essence, biosimilars are the generic form of biologics. Biosimilars have the potential to decrease the
burden of the high cost of biologic therapies by providing alternatives to the branded products.
Given the proven success and overall benefit of generics in the US small molecule industry, why has
the adoption of generics biologics been so controversial? This highly debated topic has been on the
forefront of medical discussion for the past five years.
Biosimilars are considered a cost-reducing strategy for healthcare systems, therefore providing a
great deal of societal value. The U.S. Congressional Budget Office (CBO) estimated that
establishing a regulatory pathway for biosimilars would reduce U.S. expenditures on biologics by a
stunning $200 million over the period of 2009-2013, and use of biosimilar would create a cost
savings of $25bn from 2009-2018 (24). The wave of first generation biologics have, or will, expire
prior to 2014, thereby creating a platform for the entrance of biosimilars. The next chapter attempts
to decipher the current debate on introducing biosimilars regulation.
Chapter 4: Biosimilar Regulatory Pathway Debate
Biosimilars are debated globally due to many factors including the scientific complexity of biologics,
safety and efficacy issues, and lastly political struggles between the incumbents and the generic
entrants. The two main opponents in the debate are led by:
" research-based industries, including large pharma and organizations such as the
Biotechnology Industry Organization (BIO), US's PhRMA, The European Federation
(EFPIA) and Japan's Manufacturers' Association (JPMA
" generic companies, led by Generic Pharmaceuticals Association (GPha) in the US and
European Genetic Medicines Association (EGA) (15,16)
The debate is broken down into three main categories; scientific, clinical and political (Table 4).
Table 4: Key areas of Biosimilar Debate between Research based Industry and Generics (6)
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Scientific Debate: When is "similar" similar enough?
Most of the concerns revolve around the general view of proteins and how to compare the
biosimilar with its reference product. Defining what 'similar' means and trying to interpret what
tests and analysis need to be performed to demonstrate bio-equivalence will be critical in paving the
path for biosimilar entry into multiple markets worldwide. There are two main factors to consider
when evaluating biosimilars from a scientific point of view: comparability and
substitution/interchangeability (2,37).
Comparability: While considering the R&D and manufacturing for biologics, Professor Charles
Cooney at MIT noted that the key question to ask is why would a product fail. In the biosimilar
industry, what does it mean for a product to fail? The choice of a reference product becomes critical
in understanding the biosimilar and the specifications it must meet. Determining bioequivalence is a
difficult task in the biologics space. Not two products (innovator's and biosimilar) will share exact
comparability because they are produced by two different manufacturing methods. (Note: The
manufacturing process of the reference product is proprietary information, and therefore not
disclosed to the biosimilar companies. Biosimilar companies are forced to debated topics is how will
regulatory bodies will evaluate comparability without having the manufacturing process details of the
reference product. Large pharma is concerned about having to provide their trade secret
manufacturing information as well as safety and effectiveness tests to regulatory bodies in order for
biosimilars to be fully evaluated.
Substitution/Interchangeability: Since the biosimilar is 'similar' but not identical to its reference
product, can it be interchangeable with the same guidelines as pharmaceutical generics? Because of
the current limitations of analytical methods and difficulties in manufacturing a consistent product, a
biosimilar product cannot be determined to be identical to its reference product. Therefore, in order
for interchangeability between the innovators product and the biosimilar, therapeutic equivalence
data will need to be provided. However, there is still the debate as to what the equivalence data
should consist of. A strong understanding of the structural relationship of a protein will be critical
key for regulators to determine bioequivalence. This structural-activity relationship (SAR) plays such
a pivotal role in multiple product-quality attributes (Figure 6)(37,39).
Structure-Activity Relationships (SAR):
Mining SAR for its impact on other product quality attributes
Pr I
Figure 6: Structure-Activity Relationship as defined by Robert L. Zeid(39)
Table 5 provides a list of the main factors to compare between innovator and biosimilar, and
standard industry analytical tools. There is no standard guideline for analytical tools that must be
used to characterize proteins, which makes comparisons between proteins extremely difficult.
Is the Amino Acid Sequence the same? Mass Spec
X-ray Chrystallography, multi-
dimensional NMR
Flourescent tricoscopy
Table 5: Main Factors for Characterization of a Protein to determine Bioequivalence between Reference Product and Biosimilar.
Does it have the same tertiary (3D) structure?
Sensitivity/Specificity
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Glycosylation: Stumbling Block for Determining Bio-Equivalence
Glycosylation is an example of biologic differences between the innovator and biosimilar that hinder
the ability to decipher similarity between the two products. Glycosylation is a form of post-
translational modification that causes structural and functional changes in proteins. Glycosylation
adds complexity when comparing reference products and biosimilars, and makes characterization
extremely difficult. The main issues are that there are no precedents on how to evaluate changes in
glycoslyation in the protein, and an understanding of which form of the molecule has the greatest
impact on the clinical profile exists. Glycosylation can occur at multiple sites within the molecule.
Here are the issues in evaluating glycosylation changes:
e Do companies take the average of glycoslation across the entire molecule?
* Evaluate the glycosylation at each site and look at the percentage change from site to site
between the reference product and the biosimilar?
The details of glycosylation and its direct impact to the clinical profile of biologics have not been
examined in detail and therefore no actual guidance on how to analyze and evaluate these changes in
terms of safety and efficacy are available. Glycosylation is only one of many examples that cause
difficulties in understanding the true meaning of the changes between the reference product and the
biosimilar. (Appendix A, Interview with William Egan).
Clinical Debate
Since biosimilars are not identical to their reference products, there is consensus that some form of
clinical data will need to be submitted to show safety and efficacy. But how much? Will biosimilar
companies have to submit a full clinical trial development plan and data (preclinical, phase I, II, III)?
This is a challenging question to answer. Even though the physical-chemical profile and differences
in biological activity is known between the innovator and biosimilar product, there is still no
conclusive knowledge as to how this affects the patient. Therefore, clinical programs need to be in
place to determine how safe the biosimilar is and whether or not it has the same indications as its
reference product. The size and complexity of these programs will be dependent on the level of
understanding and interactions of the protein structure, impurity profile, and other characteristics.
Immunogenicity: Imunogenicity plays a critical role in biological products. Proteins are more likely
to engage the immune response than smaller molecules. Therefore, these immune responses can
impact the therapeutic effect of the biologic therapy and has the potential to decrease or block the
clinical effect. Research based industries call for biosimilars to provide robust post-marketing studies
to regulators, thereby ensuring that there are no adverse events secondary to the immune system
that could be potentially life-threatening.
Political Debate: Market/Data Exclusivity
Another contested conversation is the requirement for additional data and market protection
beyond the scope of a patent. In the generics market, generic companies favor none to limited data
& market exclusivity periods since they are interested in entering the market as quickly as possible.
They argue that the cost to the healthcare system increases the longer generics are kept out of the
market. However, research-based players (large pharma etc.) state that the long, costly and high
risks associated with gaining FDA approval for the innovator product warrants some sort of
'insurance policy' to guarantee it recovers its costs. They argue that patent protection does not
offset the extensive cost to bring the biologic to market due to the length of time it takes to meet the
regulatory requirements (5,7,14,20). The same arguments seen in the generics market apply to
biologics and biosimilars.
From past precedents set by the pharmaceutical generics regulation (Hatch-Waxman Act of 1984),
data and market exclusivity have been given to the innovators to ensure the development of new
therapeutic products in the future. In the biologics space, the length of time of data exclusivity is
being challenged. Research-based companies claim that a 14 year period is necessary where as other
more moderate legislation supporting a 5 year market & data exclusivity. Setting a sufficient data
and market exclusivity time limit will be critical in maintaining investments in the biologics research
while still ensuring biosimilar entrance (5,7,14,20).
Chapter 5: Biosimilar Regulation
Regulatory agents require robust monitoring systems to be in place to evaluate safety and efficacy
profiles of biosimilars. However, these agents have struggled with developing regulatory pathways
for biosimilars because of the complexity of determining bioequivalence. The risks involved in
biosimilars include a higher probability of differences in efficacy between the biosimilar and its
original counterpart, and a potential increase in toxicity due to impurities and immunogenicity(28).
Scientific technologies with the ability to determine the differences between the reference biologic
and the biosimilar do exist. However, as Bob Zeid stated, the main question is what do these
differences mean to safety and efficacy? Europe, the US, and Japan have been some of the first
movers in the global regulatory landscape to establish biosimilar pathways and develop a rationale
for establishing bioequivalence. Below is a comprehensive explanation of these three pathways and
how a biosimilar company should address the regulatory requirements.
Europe's Regulatory Guidelines for Biosimilars
The EU has the longest established biosimilars regulatory pathway, with the creation of The
European Medicines Agency (EMEA) Biosimilar Regulatory process, enacted in 2005, which is
overseen by the Committee for Medicinal Products for Human Use (CHMP). Since its inception in
2005, there has been successful entrance of biosimilars in the following categories: recombinant
human growth hormone, epoetin alfa and fligrastim.
The structure of the EMEA approval process is strategically framed to adjust for each individual
biosimilar. According to Lorna Brazell esq., the approval process is still fairly new and there are very
few past precedents to determine the timescales for development and assessment of biological
medicinal products. Therefore, it is still in nature a case-by-case process. There is still uncertainty
from both the regulators and companies of what information is needed in respect to a new
application based on claimed comparability to a reference product. Since the regulatory body does
not mandate specific reference products, each application may introduce a new biologic product as a
'reference product' that has not been used in previous biosimilar applications. Therefore, it will
require time before the EMEA has a better understanding of how to determine bioequivalence
between two products. The regulatory pathway also allows for continued dialogue between the
biosimilar innovator and the regulatory body to carefully monitor the process, which includes
manufacturing process guidelines, pre-clinical and clinical guidelines.
The regulatory approval process functions as follows (Figure 7):
1. Companies submit an application for "Similar Biological Medicinal Products".
2. Companies must prove their biosimilar products demonstrate bioequivalence and pass safety
& efficacy tests. The biosimilar producers must choose a reference product. (Refer to
Choice of Reference Product pg. 32)(9)
3. Quality Standards: The CHMP guidelines (BWP/49348/2005) provide robust guidelines for
quality standards of the biosimilar in the manufacturing process, formulation studies,
comparability studies and analytical methods (Refer to Quality Standards pg. 33-34) (11).
4. Non-Clinical/Clinical Issues: Due to the fact that biosimilar are 'similar' to their reference
product and not identical, it is crucial to have data on both animal and human reactions to
the product. Guidelines are provided under CHMP/BMWP/42832/2005. [Refer to Non
Clinical and Clinical Issues pg. 34-36) (10).
Regulatory Guidelines for Similar Biological Medicinal Products
Non-lir
Quali
ica/clinica
Figure 7: The Regulatory Guidelines for Similar Biologic Medicinal products as instructed by the European Medicines Agency
(EMEA)(9,10,11).
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Choice of a Reference Product
Choosing a reference product is critical for biosimilar innovators to successfully manuever the
regulatory approval process in any market. Specifically in the EMEA, the choice of the comparable
reference product is given to the biosimilar innovator. The reference product must already be an
approved biologic in accordance with Article 8 of Directive 2001/83/EC (Figure 8)(9). Once the
reference product is established, comparability tests including quality, safety and efficacy testing
must be completed.
Strict guidelines must be adhered to in regards to the reference product. They include:
e In terms of the molecular nature of the biosimilar, it must have the same active substance as
the reference medicinal product.
" Pharmaceutical form, strength and route of administration must be identical.
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Figure 8: The Three Step Filter Process to Choosing a Reference Medicinal Product(9). First, a biosimilar innovator will have to narrow down
its choices of reference products to those that have already gain approval through the biologics new application process in the EMEA (based on
Article 8 of Directive 2001/83/EC). Second, the reference product and biosimilar must have the same active substance. Last, comparable tests, both
in term of biological analysis and clinical studies, need to be performed to show similarities and differences between the two.
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Quality Standards
The EMEA provides quality guidelines throughout the biosimilar development process. The
following is a breakdown of the requirements and guidance given for each of the steps.
Manufacturing process: The manufacturing process must be developed and optimized with state of the
art technology and accumulated knowledge up to the present time of development. The quality of
the biosimilar will be defined by the characteristics of the molecule compared to the reference
product and the process, and it must demonstrate consistency and robustness throughout the
process (11).
Formulation Studies: Studies will need to be conducted to test the formulation of the biosimilar.
These studies will need to prove stability, compatibility and integrity of the substance for its
indicated medicinal use (Figure 9) (11).
Stability
-With excpents. -In termu of biology
diluents, and and phsco
packaging material thenmlsty
Figure 9(11): Three Deomnstrable Features of the Forumlation Studies: The studies should be able to demonstrate that the
proposed formulation is stable, is compatible in regards to excipients, diluents and packaging material and lastly, that the integrity of
the substance be maintain in regards to its biology and physico-chemical.
Comparability Studies: Comparability test with the reference product must be conducted and
submitted to the EMEA. It is not expected that the quality attributes of the biosimilar and reference
product will be identical. However, the biosimilar manufacturer must submit justification for any
minor structural differences and/or impurity profile of the two biologics (11).
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Compatibility Integry of theSubstance
Analytical Methods: One of the key requirements for generics is its similarity with the branded
product. It is critical in the case of biologics that robust analysis is done to evaluate as many
different factors to ensure quality of the product. Figure 10 showcases the five main areas that need
to be consider while determining which analysis to conduct(1 1).
Suitability of available
analytical methods
Validation of
analytical methods
Biological activity Purity/I mpu rity profile
Specification
Physico-chemical
Primary and higher
order structures
Physical properties
Figure 10: Main considerations on analytic procedures(11)
Non-Clinical and Clinical Issues
Non-Clinical Studies: The purpose of non-clinical studies is to understand the structural
components of the product and use this information to detect any possible differences between the
biosimilar and the reference product. Some of the key variables that will be monitored in these
studies are stability, characterization, toxicology, mechanism of action, absorption, and metabolism.
Although the EMEA recommends providing both in-vitro and in-vivo data (Table 6), they grant
Composition
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Analytical method Considerations
biosimilar developers the final scientific decision of what type of assays, animals models, and test
would be most sufficient in providing data for safety and efficacy profiles (10).
In Vitro Studies Require assays such as receptor-
binding studies or cell-based assays
In Vivo Studies Pharmacodyamic and toxicity
studies; concern with dose regiment
Table 6: Non-Clinical Studies: In Vitro and In Vivo(1O)
Clinical Studies: These requirements are dependent on past knowledge gained through the reference
product's experience in clinical trials. It is strongly recommended that the clinical trial strategy be
developed with the data from the final manufacturing process, which represents the most robust
information on the quality profile of the batches that will be used in commercialization. The clinical
comparability studies are a three-step process (figure 11)(10).
Step 1: Design and conduct pharmacokinetic (PK) studies that investigate the dose design (single,
steady-state or repeated). Factors for biosimilar companies to be aware of during these tests are
differences in half-life, absorption and bioavailability and lastly differences in the elimination
characteristics between the two products (biosimilar and reference).
Step 2: Design and conduct pharmacodynamic (PD) studies that demonstrate therapeutic efficacy.
Step 3: Either PK/PD or efficacy studies will be required. Comparative PK/PD studies can
demonstrate clinical comparability if the following conditions for the reference product are well
characterized: PK, PD, relationship between dose/exposure, and one PD marker is accepted as a
surrogate marker that is compared to the dose/exposure of the biosimilar.
Guide~w: ICH topic E10
Figure 11: Three Stepwise Comparability exercise(1O)
The pre-authorization clinical studies are normally insufficient for all potential differences and
adverse effects to be realized. Therefore, to ensure full safety to patients, post-approval phase
monitoring will need to be continued and the data collected will be submitted to the EMEA.
Biosimilar companies are required to submit a risk management strategy and pharmaco-vigilance
plan to the EMEA that maps out the course of action the company will take in the case that
potential risks are realized post-commercialization (10).
Immunogenicity: Antibody-Testing Strategy
The immune response against these therapeutic biologics plays a critical role in how safe they are for
patients. The immunogenic potential is greatly influenced by multiple factors, including the nature
of the active substance, impurities, stability of the product, and route of administration.
The role of immunogenicity needs to be considered in all clinical trial designs, specifically in events
such as hypersensitivity, infusion reactions, autoimmunity and loss of efficacy. Table 7 provides a
list of all the factors that need to be considered in the antibody-testing strategy, as directed by the
EMEA(9,10,11).
.... .................... ....... .
1 Must use state of the art methods
2 Tests must optimize for sensitivity & specificity
3 Screening test must detect low titre and low affinity
antibodies
4 Follow domestic and international standard
5 Justify periodicity and timing of sampling for testing
of antibodies
6 Require one-year follow up data for pre-licensing
Table 7(9,10,11): Antibody Testing Strategy per EMEA Regulation: Provides six requirements that need to be include in the submission of
the antibody testing strategy to the EMEA for biosimilar approval.
Full Regulatory Guidelines as Provided by the EMEA
In the five years since the introduction of biosimilar guidelines in the EU, there has been continuous
re-evaluation of the process and introductto determine bioequivalence. Table 8 provides a
comprehensive list of the updated CHMP guidelines for each of the biologics product categories.
As each new reference product is evaluate for the major bucket categories, new guidelines are
introduce to address some of the findings found in that process. The EMEA has categorized
biosimilars as follows:
" Biological products containing biotechnology derived proteins as active substances, which
cover the first generation biologics (Epo-alfa, G-CSF, recombinant human insulin)
* Immunologicals such as Vaccines and Allergens: These biologics are highly complex, and
therefore the ability to characterize at a molecular level may not be possible under current
technology norms. The EMEA is will keep a sharper eye on these biosimilar applicants to
ensure patient safety.
* Blood or Plasma-Derived Products and their Recombinant Alternatives: Biologics under
this category are required to meet stricter safety and efficacy requirements as required for
'new products' due to the complex and variable physico-chemical, biological and functional
characteristics of the products.
Development Pharmaeutics for Biotechnological and Biological Products
UFMV/QWF/1
55/96
Guidance on Quality of Biotechnological Products: Stability Testing of CPMP/ICH/13
Biotechnological/Biological Products 8/95
Guidance on Specifications: Test Procedures and Acceptance Criteria for CPMP/ICH/36
Biotechnological Biological Products 5/99
CPMP/ICH/30
Preclinical Safety Evaluation of Biotechnology-Derived Product 2/95
Name Document
Guideline on similar bionogical medicinal products containing CHMP/BWP/4
biotechnology-derived proteins as active substances Quality Control 9348/2005
Guideline on similar biological medicinal products containing
biotech nology-derived proteins as active substance: non-clinical and CHMP/BWP/4
clinical issues 2832/2005
Annex Guidelines: Non clinical & clinical Issues- guidance on products CHMP/32775/
containing Recombinant Human Insulin 2005
Annex Guidelines: Non clinical & clinical Issues- guidance on products CHMP/94528/
containing Somatropin 2005
*6 s se - a - .seA - -
Guidance on Pharmaceutical and Biological Aspects of Combined CPMP/BWP/4
Vaccines 77/97
CPMP/BWP/2
Guidance on Cell Culture Inactivated Influenza Vaccines 490/00
CPMP/BWP/2
Guidance on Harmonisation of rEqquirements fo Influenza Vaccines 14/96
Points to Consider on the development of Live Attenuated Influenza CPMP/BWP/2
Vaccines 289/01
CPMP/BWP/4
Guidance on Allergen Products 63/97
CPMP/EWP/4
Note for Guidance on Clinical Evaluation of New Vaccines 63/97
Name Document
CPMP/BWP/2
Note for Guidance on Plasma-Derived Medicinal Products 69/95
Note for Guidance on the Clinical investigation of Human Normal CPMP/BPWG/
Immunoglobulin for Subcutaneous and Intramuscular use 283/00
Note for Guidance on the Clinical Investigation of Human Plasma CPMP/BPWG/
Derived Factor VIII and IX Products 198/95
Note for uidance on the clinical Investigation of Recombinant Factor VIII CPMP/BPWG/
and IX Products 1561/99
Note for Guidance on the Clinical Investigation of Human Normal CPMP/BPWG/
Immunoglobulin for Intravenous and/or Intramuscular Use 575/99
Table 8: A comprehensive list of the published EMEA guidelines for biosimilar development and manufacturing for submission for
approval(8,9,10,11). For full viewing of the guidelines, refer to ww.emea.europa.eu.
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Case Study: Human Erythropoietin
Epoetin-Alfa is a biologic that has had successful biosimilars counterparts. A thorough analysis of
the molecule and path to market through these newly created biosimilars regulatory pathways is
provided below.
Background of Epo
The discovery of erythropoietin, or commonly referred to as Epo, occurred in the nineteenth
century through observations of blood viscosity of individuals living in high altitude climates. It was
later proposed by Friedrick Miescher that erythropoietin directly stimulates the production of red
blood cells (RBCs) by the bone marrow. Since these early observations, it has been confirmed that
this hormone, Epo, is produced in the kidneys and plays an integral role in the production of RBCs.
Epo is a glycoprotein that consists of 165 amino acid with a molecular weight of 34,000.
Kidney
Erythropoietin
Bone Marrow
Rcd Blood Cells
Figure 12: Erythropoietin Production Pathway: The hormone erythropoietin is produced by the kidneys. It stimulates the bone marrow to
produce red blood cells.
Epo's therapeutic advantages are critical in the treatment of anemic patients. Anemic patients are
deficient in an adequate number of red blood cells, and therefore respond to Epo by stimulating the
.. . .............. 
molecular mechanisms of the production of RBCs. From its initial discovery, Epo's clinical uses
have increased to include the treatment of the following:
* Individuals with low hematocrit or hemoglobin counts
* Allogeneic blood transfusion patients: The administration of Epo reduces transfusion
requirements. For example, the introduction of Epo to autologous blood in a pre-donation
program can increase the yield
Overall, the introduction of Epo into medical strategies have increased the quality of life for patients
affected by low RBCs(1,8).
Amgen was the first mover in the therapeutic development of (darb)epoetin-alfa, bringing its first
generation branded product Epogen, followed by Aranesp to market in 2001. The mechanism of
action for Aranesp is that it stimulates erythropoiesis by the same mechanism as endogenous
erythropoietin. It is indicated for anemia with chronic renal failure and metastasis non-myeloid
malignancies due to chemotherapy. Since its initial introduction by Amgen, the market has been
dominated by three major players; Amgen, Johnson & Johnson and Roche (Table 9). Amgen
developed and out-licensed the European rights to Johnson & Johnson, and co-marketed the drug
as Procrit in the US. Roche's Mircera, introduced in 2007, is a longer lasting product in comparison
to Aranesp and requires monthly administration (1).
Product US market European market
Epoetin alpha Procrit (Johnson & Johnson) Eprex (Johnson & Johnson)
Epogen (Amgen) Not marketed
Epoetin beta Not marketed NeoRecormon (Roche)
Darbepoetin alpha Aranesp (Amgen) Aranesp (Amgen)
Pegylated epoetin beta Mircera (Roche)* Mircera (Roche)
Epoetin delta Not marketed Dynepo (Shire)
Eyet to launch
Source: Datamonitor DATAM ON ITO R
Table 9: Key Leaders in the Epoetin Market, European and US(29): Amgen, Johnson & Johnson, and Roche are the three key players in both
the US and European market with their products respectable Aranesp, ProcritEprex, and Mircera.
Story of a Successful Biosimilar Epo-Alfa: Binocrit
The EMEA approval of Binocrit, a biosimilar Epoetin-alfa , is an example of the successful
introduction of biosimilar through the newly formed regulatory pathway. Binocrit, HX575, was
approved on the 28* of August 2007. It underwent the recently published EMEA guidelines, which
required an application submission for "Similar Biological Medicinal Products" and strict adherence
to the clinical development program guidelines on recombinant erythropoietin. Binocrit was
compared against its reference product, Eprex, a J&J marketed therapeutic. Eprex is the European
branded name for the US products, Epogen and Procrit. Binocrit received the same indication as
Eprex, which allowed for its use in the treatment of anemia associated with chronic renal failure in
pediatric and adult patients on peritoneal dialysis. The standard method of treatment for Binocrit is
by injection using pre-filled syringes containing 1000-10000 IU of epoetin alfa(8).
The data points required by the EMEA for Binocrit to gain approval were as follows:
- Justification based on biosimilar concept: Binocrit is identical in its primary structure to the
endogenous human erythropoietin. In developing binocrit, it is produced in Chines Hamster
Ovary Cells, or commonly referred to as CHO cells.
- Biosimilar PK/PD data on Binocrit
- Studies that showed equivalent efficacy and safety data
Figure 13: Binocrit Regulatory Application Process in the EMEA(8)
Binocrit is a highlighted example of the first successful biosimilar Epoetin-alfa that was introduced
to the European market. Figure 13 provides Binorit's path to market. As Table 10 indicates, in the
past five years since the introduction of biosimilar guidelines, there have been six successful
biosimilar entrants including a second Epo-alfa biosimilar, Retacrit. Retacrit was developed from a
joint collaboration of Stada and Hospira. Retacrit is also an Epo-alfa that was referenced against
Eprex and introduced to the biologics market in December of 2007(4).
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Table 5.5 Biosimilar Approvals by the EMEA, 2006-2009
Drug Type Reference Product
Companes
Date of EMEA
Approval
Growth hormone Omnitrope (somatropin) Genotropin (Pfizer) Sandoz April 2006
Valtropin (somatropin) Humatrope (El Liy) LG Life Science/ April 2006
BioPartners
Erythropoietin Binocrit/E tin Alfa Hexal/ E ex/Erypo SandozlMedice August 2007
Abse (epoetin alfa) & Johnson)
Silapo/Retacit (epoetin zeta) E rrypo Stada/Hospira December 2007
CSF Tevagrastim/Ratiograstiml Neupogen (Amgen) Teva/Ratiopharm/ September 2008
Figrastim Ratiopharm CT Arzneimittel
Biograstim (filgrastim)
Zazio/Flrastim Hexal Neupogen (Amgen) Sandoz February 2009
(filgrastm
Table 10: Approved Biosimilars in the European market (4). There are two growth hormone biosimilars, Omnitrope and Valtropin, both
introduced in April of 2006. The next biosimilars to be approved were Epo-alfa candidates, Binocrit and Silapo, respectably in August 2007 and
December 2007. More recently, G-CSF candidates such as Tevagrastim and Zarzio were approved.
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... . .............. 
US's Regulatoy Guideline for Biosimilar
On March 23, 2010, a monumental healthcare reform bill was passed in the United States Congress
that hoped to curb healthcare costs and grant more Americans access to much needed care. As part
of this bill, an abbreviated regulatory pathway for biosimilars (Biologics Price Competition and
Innovation Act of 2009) was finally defined; significantly late in comparison to its European
counterparts (2). One of the key hindrances for the US in developing its regulatory strategy for
biosimilars was having to navigate the murky waters of the different opinions of the stakeholders.
These stakeholders include the FDA, Congress, innovators, generic companies (Biosimilar entrants)
and payers. Table 11 provides the key outcomes for each of the stakeholders with the passing of
the US's biosimilar pathway (33).
Key Players Role/Agenda
FDA
With the passing of the Healthcare Reform Act, the FDA will need
to put in place a pathway for biologics in the near term. They have
committed a budget of $5.7 million in 2011 to develop drug review
standards and other necessary preparations. This will include
developing the abbreviated guideline for biosimilars.
Congress Passed the Health Care and Education Affordability Reconciliaton
Act of 2010 on March 23, 2010, which included The Biologics Price
Competition and Innovation Act of 2009.
Innovators Previously were lobbying against the introduction of biosimilars and
a regulatory pathway. Innovators protected with extended branded
exclusivity given for 12 years. Most recently, more innovators are
commiting to engaging in the biosimilar market including Eli Lilly,
Merck, and Astrazeneca.
Generic Companies Previously were lobbying US government and FDA for an
appreviated regulatory pathway for biosimilars. Engaged in M&A
activityand collaboration efforts with large Pharma (including Sanofi
Aventis, Pfizer,etc.) to bring biosimilars to market. Have found that
biosimilar R&D developed, coupled with pharma's large scale
manufacturing knowledge and marketing penetration is critical to
success in this space.
Payors/Reimbursement
The Centers of Medicare and Medicaid will dictate the billing code
for biosimilars. At entry, the biosimilars will most likely receive the
same billing code as its reference brand. This could be potentially
positive for the uptake of biosimilars, since initially physicians will
receive a higher selling price based on the current systems's
Average Selling Price (ASP) system. This may be negative if the
branded companies raise their price, thereby maintaining the ASP,
to allow for physicians to continue prescribing their brand.
Table 11: Key Stakeholders in the Biosimilar Regulatory Landscape(20,21,33)
Key Outcomes of The Biologics Price Competition and Innovation Act of 2009
The Biologics Act provided a strict definition of a biosimilar, which is 'a biological product that is
highly similar to the reference product notwithstanding minor differences in clinically inactive
components, and for which there are no clinically meaningful differences between the biological
product and reference product in terms of the safety, purity and potency' (2). Based on this
legislation, the FDA can accept, review and approve license application for biosimilars through a
newly formed administrative office within the Office of New Drugs. Dr. Leah Christi was
appointed in May, 2010 as the Acting Associate Director for Biosimilars and will lead the effects to
implement a biosimilar regulatory pathway. The current regulatory pathway that has accepted
biosimilar applications, 505 (b), will be slowly phased out to allow for the biosimilar regulatory
pathway (currently still in development) to be the gold standard (Figure 14). Reference products are
once again chosen by the biosimilar company, however the FDA mandates that the reference
product must be both approved and distributed in the US. (This differs from the EMEA standards,
which only require that the reference product be approved in the EMEA).
(Tobe phased out)
Figure 14: US Regulatory Pathways for Biosimilars: Prior to 2010, Biosimilars were applying through the New Drug Application (NDA) 505
(b) pathway. This pathway allows for submission of new molecular entities and drugs that had changes to previously approved drugs.
Biosimilars fit both of these categories. With the introduction of the Biologics Price Competition and Innovation Act, a new office has been
created under the direction of Dr. Leah Christi that will implemented a biosimilar regulatory pathway and all administration required for
regulatory approval.
...... ............ ..........
Biosimilar Regulatory Pathway, 2010
One of the major topics of discussion that the new biosimilar legislation tackled is the concept of
interchangeability. In order for a biosimilar to be interchangeable with its reference product, it must
meet the following three criteria:
1. Through analytical methods, it is established to be a biosimilar to the reference product.
2. It has the same clinical results as the reference product in any given patient.
3. The risk in terms of safety or diminished efficacy in alternating or switching between use of
the biological and reference product is not greater than the risk of using the reference
product without such alteration or switch.
The concept of interchangeability is still being debated. The question remains, can a biologic,
especially a complex biologic, be determined to be interchangeable with today's technology?
According to Dr. Janet Woodcock, former Chief Medical Officer of FDA, the answer is no.
Technology does not allow us to be able to predict the clinical comparability, which is dependent on
an understanding of the structural characteristics of a protein and its function. Even with the leaps
and bounds science has made in understanding the complexity of biologics, and innovated
technology that has been developed to tackle these complexities, science has not yet reached a point
to adequately determine these differences and understand what it means from a clinical sense (2).
The main problem of the new pathway is that it creates a wide range of uncertainty as to what
criteria needs to be met in order to gain approval. Biosimilar companies will need to meet with
FDA regulators during their initial formulation of a biosimilar development strategy to get a firmer
understanding of how to proceed forward at this time. The reality of the situation is that the FDA is
in the learning process of taking the biosimilar legislation and translating it into a functional
regulatory pathway (2,37). Figure 15 outlines the key stumbling blocks for biosimilar companies in
navigating the US regulatory space.
The FDA is not obligated to provide either general or product
class specific guidance documents related to the criteria that the
agency will use to determine blosimilarity or interchangeabilIty to a
reference product.
-No clear guidance of required indications or selection of appropriate
reference standards
-innovator/reference product sponsor gets 12 years of market
exclusivity
Should the biosimilar developer follow all Indications within the
reference product label? Will that be enough to get FDA approval?
-Will the FDA be more flexible than the EMEA with trials outside the
US?
*Will the FDA outweigh perceived commercial benefits over a more
intense cenical development program designed to satisfy
interchangeablity requirements?
PROBLEMS,.-
Figure 15: Problems with the 2010 US Biosimilar Regulatory Legislation(2): Concerns arise due to the vague language and lack of specific
guidelines for biosimilars to follow to ensure approval. Additionally, the biosimilar companies will be disclosing much of their proprietary
information since they will have to engage the FDA throughout their development process to ensure approval and will have to wait a significant
time interval (12 years) for the innovator's market exclusivity period to end.
Key Pointers to for Biosimilar Companies to be Successful in the US
As a company interested in pursuing a biosimilar path, the key to success will be continued dialogue
with the FDA regulators as early in the process as possible. Providing full transparency and creating
a collaborative atmosphere with the FDA in the development strategy of biosimilar manufacturing
and non-clinical/clinical tests will prevent rejection due to insufficient data or testing.. It is crucial
for companies to plan for optimal timing in their conversations with the FDA. Those companies
that already have successful biosimilars outside the US should research what additional requirements
are needed for approval by the FDA. Those in the early stages should engage the FDA in their
biosimilar development planning to obtain feedback on their choice of reference product to quality
............ ............. . .........  ............... .
and clinical design. They key stages at which biosimilar companies should get feedback from the
FDA is outline in Figure 16. This is in alignment with the nature of the biosimilar development
plan. The US guidelines are very vague, and therefore it will be in the best interest of biosimilar
companies to keep in close contact with the regulators throughout the biosimilar development
process(2,12).
Non-clinical Design
Choosing a Differences in Aayia eino eino eino
reference the mtosad imngnct oprtv rpsdfrti
product manufacturing specification for testing methods pharmacology human Phase 1
process (within comparability and toxicology
the cell line, tests studies
purification
scheme, etc.)
Figure 16: The Six Topics to Discuss with the FDA(2): Due to the lack of specifics of the current biosimilar pathway in the US, it will be
critical to engage with the FDA throughout the biosimilar development process and get feedback on data from the manufacturing phase, non-
clinical and clinical phases.
Japan s Regulatory Guideline for Biosimilar
In March 2009, Japan's regulatory agency, PMDA, issued a final guidance for biosimilar approval. It
was second behind the EMEA to provide vigorous guidelines for biosimilar companies interested in
entering the Japanese market. However, it matched its predecessors in developing a guideline that
allowed for flexibility to incorporate evolving science technology and openness to industry wishes
while still maintaining public safety as its number one concern (15,16,28,30). Table 12 provides the
Japanese regulatory checklist for biosimilar entrants.
........... ............. ................
Action Re uired Description Checked
Develop plan based on prior
knowledge. Need to site previous
cases with significant glycan
heterogeneity, established
Manufacturing Process manufacturing processes and
la Development Plan characterization results.
Need to address structure analysis,
physicochemical properties, and
lb Characterization bioactivity
1c Drug Product Design
1d Stabili Testin Stress and acceleration testin re uired
3a Types of Comparative Studies
Evaluation of impact of varation in
heterogeneity from higher order
structures of posttranslational
modicification. Compared to results
Structural Analysis and from bioactivity, in vivo kinetics and
3ai Physicochemical Properties immunologic properties results.
Required to conduct in vivo bioactivity
3aii Bioactivity studies
3aiii Immunologic Response
3b Specifications and Test Procedures
3c Non-Clinical Studies
Provide report on toxicity of
antibodies - are they neutralizing?
What are the new pharmacokinetics?
3ci Toxicology Impurit .rofie required
3ciiPhraooiaStde
bio etiuival n throuh biologicall
will determme11 leng-1h &, nubedo
Step 4 Clinca studies, GuIidelin"s cIInical tils recl i .
Verify pharmacokinetic bio-
PK/PD studies (Pharmacokinestic equivalence and compared to
4a and Pharmacodynamic) reference product
To validate efficacy and safety of
biosimilar on humans. To
demonstrate bio-equivalence/quality-
4b Comparison of Clinical Efficacy equivalence
Further studies of immunogenicity.
Power study to be able to see results
4c Verification of Clinical Safe of im uri rofile.
Patient follow up Post immunogenecity studies
Table 12: The Five Requirements for Biosimilar Approval through the Japanese Regulatory Agency(28): The first step is the
manufacturing guidelines, which requires a strict adherence to the manufacturing process plan and gaining structural knowledge on the
biosimilar. The next step 2 and 3 is doing comparative non-clinical studies with the reference product. The step 4 is the clinical trial design.
Last, Japan's regulatory agency requires post-marketing data.
Successful Biosimilar Entrants in the Japanese Market
Japan has seen the introduction of two biosimilars in the past year: the introduction of Omnitrope
(somatropin) and an epoetin alpha. The biosimilar epoetin alpha was developed through a
collaboration between Japan Chemical Research (JCR) Pharma and Kissel in January 2010
(15,16,30). As of yet, no officiall data has been released to show the market up take of these
biosimilars. However, the regulatory pathway in Japan has successfully provided guidelines that
enable biosimilar products to enter the market.
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Commonalities among all the Regulatory Pathways
The EMEA, FDA and PMDA have all committed to biosimilar guidelines to allow biogenerics in
the market. Although each pathway differs in its requirements, there are a few common threads
among all three.
It is a learningprocess for allregulatory agencies. Biologics are extremely complicated and
defined by the manufacturing process rather than the components of the molecule. Since this is a
new venture for all the regulatory agencies, there is a 'learn by experience' philosophy on how to
determine bioequivalence and what data points are required to make these conclusions.
Patient safety comes first. All the regulatory agencies have been conservative and cautious in their
approach to giving full entrance to biosimilars. The concerns of variations in clinical profile and
immunogenicity have caused regulatory bodies to not automatically grant interchangeability between
the reference product and the biosimilar.
Clinical tests will be required. Noting the above, clinical test will be required to ensure that it is
safe within the patient population and that it behaves in the same manner as its reference product.
Chapter 6: Discussion
Returning to the main thesis questions, it can be confidently stated that in the major global markets
there is a regulatory path for biosimilars. Taking into considerations all the different variations in
the market specific regulatory pathways, the biologics and biosimilars requirements are outline in
Table 8. There is continued debate as to the test requirements for biosimilars and what the results
will need to be in order to gain interchangeability status. These debated topics are highlighted in
Table 8.
rnysic narauewnuun. m wVa6m, y&ma U1'. X X
secondary structures, etc.
Chemical Characteristics: molecular formula, chemical
strucutre
Specifications of drug substance (active ingredient) X X
stability X X
purity X X
consistency of manufacturer of the drug substance X X
Description of analytical testing performed on the
manufacturer's referece standard lot and qualitying lots X X
to characterize he drug substance.
pharmacokinetic/pharmnacology/toxicology X X
studies for absorportion, distribution, maion i and X X
dacto with e gi animals
F ~X
Bioavaciilt/i oiclnce studies (very__few
Description and analysis of each cnre clinical mclg
stuy obth mdiiaprdc(om snof human X ?.
study _ _ _
Clinical Effectiveness fr the clinical indications. X
Evidence for dosage and administration required.X
Clinical Safety: studies of assessment of absorption,
dlistribution, metabolism, and/or elimination of drug
Sumimary of benefits and risks of the medicinalX?
. P
X X
X X
Saiy u t Ro r X X
toubmexission) Yw i.X
Table 13: Regulatory Checklist for Biologics and Biosimilars
..............
..................    .
Do biosimilars create value to the healthcare system? Absolutely! The key driver for success of
biosimilars and decreasing costs is that they capitalize on past biologic experience. It is agreed upon
by both parties (research-based industry and generics) that biosimilars contribute to cost-savings in
the following areas:
Prevention of Failed products: Biosimilars have a 'blueprint' that was created by the
reference/innovator's product experience for the entire process including R&D, manufacturing
protocol, clinical trial development and data, and marketing/sales. Therefore, the risks associated
with failing at different milestones during the development phase are significandy decreased, if not
obsolete. Therefore, biosimilars add insurance for developers that their investment will not carry the
high risks that are usually associated with biologics. The cost associated with failed products can
reach the upward limits of $1.5bn if taken through phase 111 trials, which is the average cost of
new biologics in 2005(37). The success of a new biologic passing a clinical trials is still relatively
low, ranging 11.5%-21.5% (37).
Time: The majority of time is spent in the development process, and trial and error approach to
innovation. The average innovative biologic product takes 10-20 years to develop. Biosimilars are
decreasing this timeline by at least half! The biosimilar savings from eliminating failed products and
decreasing time to market represents in the upward range of 80% of the overall total cost of
biologics.
The areas that are still debated are how much clinical trial data will be needed to ensure safety and
the issue of interchangeability and substitution. More emphasis is being placed on these two areas
than is realistically justified.
Clinical Trials: From the perspective of the generics companies, they are trying to avoid the
additional cost involved in clinical trial studies. Cost savings for generic companies occur in R&D
expenditure (or lack thereof), and an abbreviated timeline. Therefore, the 'additional cost' argument
of having to do clinical trials, which their counterpart generics in the pharmaceutical industry avoid,
is trivial. The need to provide confidence to the regulatory agencies that their biosimilar product is
safe for public use appears to outweigh the cost argument.
Interchangeability/Substitution: In terms of interchangeability/substitution, opponents claim that
the current science technology does not support automatic interchangeability or substitution. They
also state that variations in immunogenecity are too great of a risk to allow for interchangeability.
These once again are faulty roadblocks that are being used to prevent branded biologics from losing
their market share and high margins. First, within the original reference products are variations in
compositions that occur from one batch to another. This is inherent in the making biologics.
Recent advancement in biologic analytical tools allow for a robust understanding of the molecular
composition of these complex molecules. According to Dr. Martin Schiestle from Sandoz and
additional respected members of the science community (Refer to Appendix A), 'the regulatory
bodies have created approval processes for biosimilars and rigorous comparatives testing at all stages
of development that provide a sound scientific basis for interchangeability' (16). In other words, we
have the information to allow for pharmacist to interchange between branded and biosimilars drugs
comparable to that for small molecules and their generic counterpart.
A question to ask while discussing interchangeability is why do biologics continue to be evaluated
through a process driven method instead of a product driven method. As discussed earlier,
historically biologics were too complicated and the molecular & cell biology was poorly understood
to be able to evaluate with confidence the originator and generic product. However, as modern
technology has evolved to be able to characterize biologics, regulators should consider whether the
process driven method of evaluating biologics is necessary. Interchangeability could potentially be
determined by comparing the end active substance, thereby causing greater ease in creating
regulatory guidelines.
Future of Biosimilar Regulation
So what is next for biosimilars regulation? As of 2010, there are three established biosimilar
regulatory pathways. The FDA, EMEA and PDMA all share the common goal of placing the
patient safety above all other criteria when designing the benchmarks within their approval process.
Is creating a global regulatory pathway feasible in the future?
One key issue is the nature of the reference product from one country to the next. First there is the
question as to whether or not the reference product is approved and/or distributed in the country.
Europe requires that a chosen reference product for a biosimilar must be both approved and
distributed, while the US only requires that it be approved in the US market. A second issue is
whether the reference product, even under the same name, is an identical product throughout
different regions.
In order to confidently resolve this issue, countries will have to return to their country specific
reference product and determine whether the biosimilar and reference product are comparable in
each region. Therefore, the value add of a global regulatory path is lost since both clinical and non-
clinical tests will need to be conducted in each region where the same reference products are actually
different.
In conclusion, regulatory paths have been established, therefore providing greater incentives for
companies to develop biosimilars. Although there is still much uncertainty in the debate as to how
to regulate these molecules, a comprehensive checklist based on the current known information is
created in Table 14. Therefore, a checklist for biosimilars milestones has been created that
incorporate the three regulatory agencies' rules (Europe, US and Japan). The next step for the
future of biosimilars is to determine a consensus for the specifics in characterizing biologics and
clinical trials (highlighted in yellow).
Completed Regulatory Guideline Checklist
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Chemical Characteristics: molecular formula, chemical X X X X
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Specifications of drug substance (active ingredient) X X X X
stability X X X X
purity X X X X
consistency of manufacturer of the drug substance X X
Description of analytical testing performed on the
manufacturer's referece standard lot and qualitying lots X X
to characterize the drug substance.
pharmacokinetic/pharmnacology/toxicology X X X X
studies for absorportion, distribution, metabolism and X X
excretion of the drug in animals
X X
%it of allcot Apens used in the Mnanufctur
(snhei/ioaio/urfcainof drug substance, X X X X
bi X X X
t xd W
X X
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Bioavailabihity/bioequivalence studies (very few X X ?
biologics will have such data)
Description and analysis of each clinical pharmacology
study of the medicinal product( comparison of human X ? ?
data with animal data)
Pharmacokinetic & Toxicology Studies X X ?
Description and analysis of each controlled clinical
study
Clinical Effectiveness for the clinical indications. X
Evidence for dosage and administration required.
Clinical Safety: studies of assessment of absorption, X?
X X?
distribution, metabolism, and/or elimination of drugt
Summary of benefits and risks of the medicinal X X?
product in its intended use
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Table 14: Regulatory Checklist for Small molecules and its Generic Equivalent, and Biologics and its Biosimilars
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Appendix A: Interviews
Name (Last,
First) Title Company
Bird & Bird LLP,
Brazell, Lorna Partner, Intellectual Property UK
Strategic
Builder, Stuart PhD CEO BioDevelopment
Robert S. Haslam Professor of
Cooney, Charles PhD Chemical Engineer MIT
PharmaNet
Egan, William Vice President Consulting
Alnylam
Ertel, Shara Director, Business Planning Pharmaceuticals
Sr. Director, Global Oncology &
Cardiopulmonary
Commercialization and Business
Gottschalk, Adrian Intelligence & Operations Biogen Idec
Kotlikoff, Laurence Professor of Economics Boston University
Vice President, Scientific and Alnylam
Pollard, Stuart Business Strategy Pharmaceuticals
Rossi, Christina Sr. Director Biogen Idec
Rossomando, Anthony Alnylam
PhD Senior Director Pharmaceuticals
Sensabaugh,Suzanne VP, Regulatory Affairs Panacea Pharma
Sinclair, Alistair Head of Strategic Analysis Datamonitor
Account Manager, Customer PAREXEL
Thompson, Paul Strategy Consulting
Zeid, Robert Principal Consultant TLI Development
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Appendix B: Assessment of Biosimilars Market 2010
Overview of Generics Market
The worldwide generics market continues to exist and maintain its stronghold in the 'mature
generics market', which consists of the US, Germany, and the UK. The US and Western European
markets are expected to grow at 7% in the upcoming years, with the emerging economies showing
an even more promising landscape with a growth rate of 16%. These three countries account for
over $70bn in generic sales, which accounts for 9 0% of total major market generic
sales (29,30,31,32).
The US continues to be a prime market for uptake of generics because of customer acceptance.
According to Datamonitor, the average erosion of first generics entry after three quarters in the
market was approximately 80%. Germany and the UK followed in second place in terms of volume
erosion (Figure 17).
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Figure 17: Quarter by Quarter Summary of Generics Uptake after Initial Launch(29): The US has the fasted uptake of generic
drugs, representing 85% of the market after 3 quarters. Japan has the slowest uptake, representing the population's loyalty to branded
products and distrust of generics.
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Opportunity for Biosimilar Growth: Patent Cliff
2010-2014 opens the door for generic players with key patents expiring in this timeframe. Estimates
in the upward range of $11Obn in global sales are exposed to generic competition through 2014. Of
this estimated profitability exposure, $40 bn represents biologics erosion. This is a key driver of the
emerging biosimilar market, especially since biologic therapies are rapidly growing with extraordinary
high prices. With biosimilars, priced at about 30% discount to the brand product, healthcare payers
are expected to make a huge savings across all major markets(4,29,30,31).
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Figure 16: Global Sales Exposed to Biosimilar Erosion Through 2020(4): The global sales exposed to biosimilar is $40bn in the next five
years, representing the loss of patent protection by branded biologics.
In the developed countries, innovators' biologic therapies have enjoyed patent protection, which
included a period of twenty years of exclusivity rights and in some cases, additional period of data
and market exclusivity from biosimilars. Epoetin Alfa, Filgrastim, GCS-F, and human growth
horome are expected to lose patent protection in the near future, or already have. These first
generation biologics represent the 'low hanging fruit' for generic. Table 15 clearly shows the high
revenue biologics that have or are expected to expire in the near future(4).
.....  .
Estimated
Patent Expiry
USKmaor
European
Markets
Drug Drug Type 2008 Sales(bn)
Expired Expired Prevnar/Prevenar (pneumococcal conjugate vacdne Wyeth) Vaccine 2.72
Expired Expired Arapdfnsdatard/Mlxtard/Novln (human Insulin, NOo Nordisk) Insulin 2.33
Expired Expired Avonex (Interferon beta-la, Blogen idec) Interferon 2.20
Expired Expired Rebif (Interferon beta-la, Merck KGaA) Interferon 1.94
Expired Expired NeoRecormon/Epogin (epoetin beta, Roche) Erythropoletin 1.68
Expired Expired Betaferonfetaseron (Interferon beta-lb, Bayer) Interferon 1.67
Expired Expired Pegasys (peginterferon alfa-2a, Roche) Interferon 1.52
Expired Expired Genotropin/Nutropin (somatropin, Pilzer/Genentech/Rochelipsen) Grth hormone 1.34
Expired Expired Humulin (human Insulin, ElI Lilly) Insulin 1.06
Dedared 2011 Lovenox (enoaparin, Sanoi-Aventis) Hepadn product 4.00
unenforceable
2009 2010 Enbrel (etaercept Wyeth/Amgen) AIFP 6.23
2010 2010 AranesplNespo (darbepoetin alfa,ArngenKyuwa Hakko Kirin) Erythropoletin 3.58
2010 2014 Lantus (insulin gargine, Sanonf-Aventis) Insulin 3.58
2012 Expired (epoetn alfa, Amgen/.ohnson & Erythropoletin 5.07
Table 15: Biologic Drugs Expiring in the Next 10 years(4): The three top Epoetin branded biologics, Aranesp, Epogen, and Epogin have all
expired as of 2010. This is a key opportunity for epoetin biosimilars in both the global, and US market.
Based on the model in table 16,and taking into considerations forecasted biosimilar sales by
Datamonitor, the global and US predicted sales through 2019 are $200bn and $150bn respectably
(Table 16). Even if biosimilars maintain its current market penetration of less than 2 %, they will still
reach $2bn in sales by 2019.
Global Sales
(In millions) 40000 42000 44100 46305 48620 51051 53604 56284 59098 62053
PV: r= 20% 33333 29167 25521 22331 19539 17097 14960 13090 11454 10022
NPV 196513
US Sales (in
millions) 30000 31500 33075 34729 36465 38288 40203 42213 44324 46540
PV: r=20% 25000 21875 19141 16748 14655 12823 11220 9817 8590 7516
NV1473851
Predicted
1.6% market
capture 96 208 381 570 716 817 858 901 946 993
PV: r= 20% 80 145 221 275 288 274 239 209 183 160
NPV 2074
low capture
at 10% 600 1302 2381 3565 4473 5105 5360 5628 5910 6205
PV: r= 20% 500 904 1378 1719 1798 1710 1496 1309 1145 1002
NPV 12962
High Capture
(25%) 1500 3255 5954 8914 11183 12763 13401 14071 14775 15513
PV: r= 20% i 1250 2260 3445 4299 4494 4274 3740 3272 2863 2505
NPV 32404
Table 16: Forecasted Biosimilar Global Sales from 2009-2010: The growth rate for the biologics industry was assumed to be at 5% through
information gathered from Datamonitor pharmaceutical reports, 2010. Looked at three different potential market capture percentages to determine
........... --- ------------
predicted biosimilar revenue in the US. First, a continued market penetration of 1.6% for the future (current rate as of 2009). Second, a low market
capture of 10%. The last is a high market capture of 25%, which is in line with the European biosimilar market capture percentage.
Focusing on erythropoietin biologics, the three key players that enjoy 98% market share,
representing about $10bn in global sales, will all be off patent by the end of 2010(4).
* Epogin, by Roche, which took in $1.7bn in 2008, has already expired and held third place
amongst its competitors.
* Arasnep, the first erythropoietin drug to enter the market, had approximately $3.8bn sales in
2008 and will expire in all major markets by the end of 2010.
* Epogen, also called by branded name Procrit, is marketed by both Amgen and J&J is the
largest player in the market, with 2008 profits reaching $5bn.
Table 3.17 The Erythropoietin Market, 2008
Marketing 2003 Sales Market Share
Comayy ($bn) (%)
Estimated Patet xp
US Major European
Markets
rexl Amgen/ 5.07 47.8 2012 Expired
EO Johnson & Johnson/
(epoetin alfa) Kyowa Hakko Kn
Aranesplies Amgen/ 3.58 33.8 2010 2010
(darbepoetin a) Kyowa Hakko Kirin
NeoReconnonEpogin Rode 1.68 15.8 Expired Expired(epoetin beta)
Other bruaded erythropoietin drugs 0.10 0.9
Biosimilar erythropoietin drugs 0.17 1.6
Total erydwopoietin drugs 10.60 100.0
Somm.e: Mi in, cowpany anwa r pots and MS tealh, 200
Notes: Data based a ex-maducrer prices
Table 17: The Global Erythropoietin Market in 2008(4): Branded Epogen, Aranesp and Epogin represent 97% of the market. With their
patents expiring, biosimilar erythropoietin drugs have an opportunity to significantly increase their market share from less than 2%.
The patent cliff has already eroded in the erythropoietin space, and it is yet to be determined how
biosimilars will be able to capture the exposed market (-$10bn). Table 17 gives the forecasted
revenue of epoetin, both global and in the US respectable. The total market opportunity for
Epoetin globally is $142bn from 2009-2010, and $100bn in the US during that same time period. In
2008, biosimilars capture less than 2% of the market, making evident that patents play a crucial role
..........
in deterring biosimilar activity. However, the changing landscape of patent protected products will
provided great incentive for both suppliers and buyers to turn biosimilars(4,29,30,31).
Fr Case p noa al e
PV: R= 20% 10,000 10,500 11,025 11,576 12,155 12,763 13,401 14,071 14,775 15,513 16,289
NPV 142 068
US Epoetin Market 7,000 7,350 7,718 8,103 8,509 8,934 9,381 9,85 10,342 10,859 11,402
PV: use rate of return
at 20% 7,0001 7,3501 7,718 8,103 8,509 8,934 9,381 9,850 10,342 10,859 11.402
Total NPV 99,4481
Table 18: Forecasted Epoetin Global Sales from 2009-2019: Assumptions used in this model are that the biologics growth rate is an annual rate of
5%. Therefore, there is a global opportunity to capture $142bn for biosimilar epoetins, and in the US around $100bn.
The high cost and high demand of biologic therapies, coupled with continued pressure to decrease
cost healthcare cost around the globe and the lost of patent protection by branded companies,
provides a perfect landscape for the emerging biosimilar market. In five years, biosimilars global
sales are expected to increase by six-fold, with growth rates doubling to 57% in 2010 (Table 19)(4).
Table 3.5 World Biosimilar Market Forecast, 2009-2014
Ye 2008 2009 2010 2011 2012 2013 2014
Biosknilar Mwket ($bn) 1.39 1.68 2.14 2.90 3.95 6.04 9.46
Growth %, year-owyear) 21 27 35 36 53 57
CAGR (%, 2008-2014) 38
Sowes: ianYin, 200
Notes- Daba based an ex-naadctier prices and excdude vacnes, 2006 tigwes we actual sales, tiew years we iorecasts
based on consant 2000 prces
Table 19: World Biosimilar Market Forecast(4): Expecting to reach $10bn in global sales by 2014
Enoetin, Global sal
............ . ..... ...... ........... ......................... .....................................................  . .. ....
10000
1i5n -n 112 (1. 11 576 12155-; 1273 i 134 1 14071 14 775 15 1 rr I 1s6289
Key Drivers of the Biosimilar Market
Drivers that can continue to allow for growth in the generics space include
* Overall social need to bring drugs to all society members: Generics erosion was found
to be highest in the US, with average peak volume and value uptake of 94.7% and 81.1%,
respectively, in the third quarter of generics entry.
* Cost-saving alternatives: Both payers and the governments, as reflected in the US
Healthcare Reform Bill of 2010, are looking to maximize medical savings by accelerating
generic uptake in the market, thereby driving down price due to competitive pressure.
* Large pharmaceutical and biotechnology players looking to bolster up their
portfolios with profitable products:
* Established Regulatory Guidelines in Key Markets: The three key markets with
established regulatory pathways as of 2010 are the US (established in March 2010), Europe
(2005) and Japan (2009). Table 4 provides a comprehensive outline of additional metrics to
consider in the biosimilar uptake between these markets(29,30,31,32).
Metric 
Market
Growth potential At
Impetus to boost volume share * A * At
Generics utilization incentives * i t it
Scrutiny of brand-generic relations A * I A * f
Generics pricing pressure f f I I -
*Germany and the UK represent markets in which considerable generic utilization incentives exist, while the same cannot be
said of France, Italy and Spain. However, these less mature markets offer greater potential for growth than Germany and the UK
5EU=France, Germany, Italy, Spain, the UK
Table 20: Metrics to Determine Generic & Biosimilar Uptake in Three Key Markets (US, EU, Japan)(29,30,31,32)
....... 
Appendix C: Additional Considerations to Improve Biosimilar Uptake
There are multiple areas of improvement that would lead to more incentives for companies to enter
this space based on potential for both market penetration success and greater profitability.
1. Pricing and Reimbursement strategies need to be in place to guarantee success for
biosimilars, and also provide profitable incentives for companies to get into this space. In
the UK, the generic drug reimbursement is regulated under the Drug Tariff scheme. This is
a complex system in which the reimbursement is re-calculated each month according to a
volume weighted average manufacturer price(30). The theory behind this method is that it
aligns reimbursement with changing market dynamics, however it disincentives
manufacturers by causing increase pressure to lower price, which in some cases are
unsustainable.
2. Conversations about the length of market exclusivity for branded products also cause
concern. The faster generics get to the market, then the overall benefit to society is greater.
Market exclusivity provides a barrier to generics by granting greater protection for branded
products. The European Commission found that the period between branded drug launch
and the first generic launch has increased by 3.5 years, from 10.5 years to 14 years(25). Factors
that contribute to this increase timeframe included reformulation and second-generation
product launches, settlements with generic companies, and brand loyalty to name a few.
Developing Frameworks and Predictive Models to Determine Bio-Equivalence
One of the continued key concerns by regulatory bodies is the overall complexity of biologics and
understanding what these differences in protein structure, impurity profiles etc., actually mean when
being administered to patients. There are so many variables that influence the product quality and
process consistency, known as the product=process paradigm. Robert Zeid of TLI Development
has proposed strategies to tackle the 'product=process' paradigm(39).
* Quality by Design (QbD): A development program that incorporates prior knowledge of
the product and process characteristics to developed a framework of relationships and how
these impact each quality parameter. The goal is to develop a predictive model of the
impact on safety and efficacy(39).
* Process Analytical Technology (PAT): A framework that allows for designing, analyzing and
controlling biosimliar manufacturing. It determines product quality by fully understanding
the biological components of the drug, desigining a manufacturing process that can show
reproducibility by taking into consideration therapeutic objectives, patient population, route
of administration and pharmacological, toxicological and pharmacokinetic
characteristics (39).
People as a key Competitive Advantage in the Biosimilar Market
Seeing that the development of biosimilar is suppose to result in a cost-saving proposition, than the
question is what skills are needed to make these cost-savings tangible? Although reference products
previous experience provides a framework to work within, it still requires some tailoring to match
the specific development plan for the biosimilars.
People are the key differentiator for the success of a biosimilar. Biosimilar development planning
requires people with a strong understanding of science and clinical medicine. They can therefore
fine tune the already established reference product protocols and be able to modify them based on
past results, new knowledge about the disease, and new technology.
These people are difficult to find. People established in the generics industry do not usually have
the scientific background to take a fine-tune look at the scientific techniques and data previously
used for the reference product and modify them based on current needs. These skill sets have not
been required in the previous pharmaceutical generic industry. These skill sets are more aligned with
scientific 'entrepreneurs' in the branded companies, which are used in innovating new products.
However, the key ingredient required to make biosimilars a success is the ability to step back, look at
past manufacturing and clinical plans from the reference product, and tailor the strategy for current
regulatory approval. This may require reconsidering whether certain tests are necessary or certain
technologies can be applied/removed from the process. This is the challenge(Appendix A,
conversation with Suzanne Sensabaugh).
